Rise and shine, everyone, another busy day is on the way. The Pharmalot campus, for instance, is buzzing as the shortest of short people leaves for the local schoolhouse and our official mascot is snoozing about. As for us, we are engaged in our usual routine of sipping cups of hot stimulation and foraging for interesting items. Meanwhile, here is your menu of tidbits to get started. Hope you conquer the world today and, of course, do stay in touch. …

Insys Therapeutics (INSY) agreed to pay $225 million to settle criminal and civil investigations into marketing practices of using kickbacks to persuade doctors to prescribe its Subsys painkiller, which contains fentanyl, a powerful and addictive opioid, STAT says. As part of the deal, an Insys subsidiary will plead guilty to five counts of mail fraud, while the company will pay a $2 million fine, $28 million in forfeitures, and $195 million to settle charges of violating the federal False Claims Act, which involves defrauding the federal government. The company must also sell the painkiller within a year.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy